Cannara Biotech Delivers Record Q2 Results as National Expansion Accelerates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2025
0mins
Should l Buy ?
Source: Newsfilter
Record Financial Performance: Cannara Biotech Inc. reported a 35% increase in net revenues to $26.6 million for Q2 2025, alongside a 52% rise in gross profit and a record Adjusted EBITDA of $7.1 million, marking the sixteenth consecutive quarter of positive results.
Market Expansion and Growth Strategy: The company expanded its national market share to 3.9%, with significant gains in Québec, Ontario, and Alberta, while activating two new grow zones to enhance production capacity and support ongoing product innovation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
